ARNUITY ELLIPTA
ICS DPI
Fluticasone furoate · GlaxoSmithKline
Active Medication & Mechanism
- Fluticasone furoate ICS50 mcg, 100 mcg, or 200 mcg per blister
Synthetic trifluorinated corticosteroid with potent anti-inflammatory activity and enhanced glucocorticoid receptor affinity. Once-daily dosing due to prolonged retention in lung tissue.
FDA-Approved Dosing by Indication
// approval varies by strength + age Asthma
3/4 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 50 mcg | Patients ≥5 years | 1 inhalation once daily Lowest available strength; for patients ≥5 years previously on non-corticosteroid therapy or low-dose ICS. | 50 mcg | FDA Approved |
| 100 mcg | Patients ≥12 years | 1 inhalation once daily For patients previously requiring medium-dose inhaled corticosteroids. | 100 mcg | FDA Approved |
| 200 mcg | Patients ≥12 years | 1 inhalation once daily For patients previously requiring high-dose inhaled corticosteroids. | 200 mcg | FDA Approved |
| Any strength | Acute bronchospasm | — | — | Not Approved Not a bronchodilator. Not for relief of acute bronchospasm. Use a SABA. |
COPD
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Adults | — | — | Not Approved Arnuity Ellipta is not indicated for COPD. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute use. Use a SABA. |